← Back to Search

Norepinephrine-Dopamine Reuptake Inhibitor

Centanafadine for Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 1
Waitlist Available
Research Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights

Summary

This trial is for kids with ADHD who are 4-12 years old.

Eligible Conditions
  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Apparent clearance and apparent volume of distribution of centanafadine on Day 14
Area under the concentration-time curve from time 0 to 24 hours (AUC0-24h) on day 14
Maximal peak plasma concentration (Cmax)

Side effects data

From 2019 Phase 2 trial • 13 Patients • NCT04081363
14%
Vessel Puncture Site Bruise
100%
80%
60%
40%
20%
0%
Study treatment Arm
Swallowed Capsules Cohort
Sprinkled Onto Applesauce Cohort

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open-label centanafadineExperimental Treatment1 Intervention
There will be multiple cohorts dosed with open-label centanafadine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Centanafadine
2019
Completed Phase 2
~300

Find a Location

Who is running the clinical trial?

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
246 Previous Clinical Trials
167,119 Total Patients Enrolled
~12 spots leftby Jul 2025